Sage for Blood Sugar & Lipids
The smallest of sage's four major clinical benefit clusters is also, in some ways, the most surprising: oral sage leaf extract at 500 mg three times daily for two to three months lowered fasting glucose, hemoglobin A1c (HbA1c), total cholesterol, low-density lipoprotein (LDL), and triglycerides and raised high-density lipoprotein (HDL) compared with placebo in people with type 2 diabetes and high blood fats, in a 2013 Iranian randomized controlled trial by Kianbakht and Dabaghian (Complementary Therapies in Medicine). An earlier 2011 trial by the same group (Phytotherapy Research) was a lipid-only trial in people with high cholesterol or triglycerides. A 2023 meta-analysis that pooled three sage trials in people with diabetes found fasting blood sugar 31.15 mg/dL lower, HbA1c 0.94 percentage points lower and LDL 19.23 mg/dL lower, while triglycerides and HDL did not change significantly. The proposed mechanism, so far shown in cell-culture studies, is carnosic acid activation of AMP-activated protein kinase (AMPK) — the same enzyme that metformin activates. The Iranian trials, the supporting mechanistic work, and the practical question of whether culinary sage at typical kitchen doses contributes anything are covered below.
Table of Contents
- Type 2 Diabetes as Sage's Newest Clinical Target
- Kianbakht 2011 — A Lipid Trial in High Blood Fats
- Kianbakht 2013 — Glycemic + Lipid Endpoints
- A Trial That Did Not Lower Fasting Sugar
- Carnosic Acid AMP-Activated Protein Kinase Activation — The Metformin Pathway
- Insulin Sensitization in Liver & Muscle
- Why Sage Also Improves Cholesterol & Triglycerides
- Alpha-Glucosidase Inhibition & Postprandial Spikes
- Carnosic Acid, Adipocytes, & Weight Metabolism
- Culinary Sage vs Therapeutic Extract Dosing
- Sage vs Metformin — Adjunct, Not Replacement
- Cautions — Hypoglycemia, Drug Interactions, Thujone
- Key Research Papers
- Connections
- Featured Videos
Type 2 Diabetes as Sage's Newest Clinical Target
Of the four major sage benefit clusters — cognitive, menopausal, antimicrobial, and metabolic — the type 2 diabetes evidence is the newest. The cognitive-function evidence dates from the 2003 Tildesley and Akhondzadeh trials. The menopause evidence rests on the 2011 Bommer trial. The sore-throat evidence rests on the 2006 Hubbert trial. The metabolic / diabetes evidence rests primarily on small trials from Iran — the 2013 and 2016 Kianbakht trials and the 2013 Behradmanesh trial in type 2 diabetes, plus the 2011 Kianbakht lipid trial — with supporting in-vitro and animal mechanistic studies from the late 2000s and 2010s.
The traditional indication is not new — sage has been used in folk medicine across the Mediterranean and the Middle East for "sweet urine" (the pre-modern term for diabetes mellitus) for centuries. What is new is testing in clinical trials. The Kianbakht trials are cited in the integrative-medicine diabetes literature, and a 2023 meta-analysis pooled three of the diabetes trials.
The diabetes trials tested sage extract against placebo in people with type 2 diabetes, in the 2016 trial as an addition to glyburide, metformin and atorvastatin. Sage extract is low-cost, the Kianbakht trials reported no adverse effects, and sage extract lowered both blood sugar and blood fats in the 2013 and 2016 trials. None of these trials compared sage with prescription antidiabetic therapy in severe uncontrolled diabetes (hemoglobin A1c above 9%).
Kianbakht 2011 — A Lipid Trial in High Blood Fats
The first Kianbakht trial was published in Phytotherapy Research in 2011. It was a trial of blood fats (lipids), not a diabetes trial, and it did not measure blood sugar. The protocol:
- 67 people with high blood fats (high cholesterol and/or high triglycerides; hyperlipidemia)
- Randomized, double-blind: Salvia officinalis leaf extract, one 500 mg capsule every 8 hours (34 people), or placebo (33 people)
- Treatment duration: 2 months
- Endpoints: fasting blood lipids, creatinine (a kidney test), and the liver enzymes serum glutamic-oxaloacetic transaminase (SGOT, also called AST) and serum glutamic-pyruvic transaminase (SGPT, also called ALT)
The findings at 2 months, compared with placebo:
- Total cholesterol, triglycerides, low-density lipoprotein and very-low-density lipoprotein (VLDL) — all lower in the sage group
- High-density lipoprotein cholesterol — higher in the sage group
- Liver and kidney tests — SGOT, SGPT and creatinine did not change significantly, and no adverse effects were reported
The 2013 follow-up trial moved to people with type 2 diabetes and high blood fats, enrolled 80 people, and measured blood sugar as well as lipids (next section). The 500 mg three-times-daily dose used in both trials was used again in the 2016 Kianbakht trial.
Kianbakht 2013 — Glycemic + Lipid Endpoints
The 2013 Kianbakht and Dabaghian trial published in Complementary Therapies in Medicine was the larger follow-up and the first Kianbakht trial in people with diabetes. The protocol:
- 80 people with type 2 diabetes and high blood fats (high cholesterol and/or high triglycerides): 40 on S. officinalis leaf extract, one 500 mg capsule three times daily, and 40 on placebo
- Treatment duration: 3 months
- Endpoints: fasting glucose, HbA1c, total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol, the liver enzymes SGOT and SGPT, and creatinine
At the end of the trial the abstract reports the difference between the sage and placebo groups as percentages, not mg/dL: fasting glucose 32.2%, HbA1c 22.7%, total cholesterol 16.9%, triglycerides 56.4% and LDL cholesterol 35.6% (all lower with sage), and HDL cholesterol 27.6% (higher with sage). Of the two early Kianbakht trials, only this one was in people with diabetes — the 2011 trial measured blood fats only — and both come from one research group in Iran.
A 2023 systematic review and meta-analysis (Abdollahi and colleagues) pooled three randomized trials of sage in people with diabetes. Sage lowered fasting blood sugar by 31.15 mg/dL, HbA1c by 0.94 percentage points, total cholesterol by 43.64 mg/dL and LDL cholesterol by 19.23 mg/dL, and also lowered blood sugar 2 hours after meals. Triglycerides (p=0.09) and HDL cholesterol (p=0.18) did not change significantly, and liver enzymes did not change significantly. No specific side effects were reported in the three trials. Because only three trials were found, the authors called for stronger clinical trials.
The 2013 paper also reported on safety: no adverse effects were reported, and the liver enzymes (SGOT, SGPT) and creatinine did not change significantly compared with placebo over 3 months at 500 mg three times daily. The standardized leaf-extract route (as opposed to essential-oil capsules) avoids the thujone exposure that would limit higher-dose internal use of sage.
A Trial That Did Not Lower Fasting Sugar
A second Iranian group (Behradmanesh and colleagues, 2013) ran a double-blind trial in 80 people with type 2 diabetes whose disease was not well controlled. Half took Salvia officinalis and half took placebo tablets, three times a day for three months. Blood sugar 2 hours after meals and cholesterol fell significantly in the sage group compared with placebo, but fasting blood sugar and HbA1c did not change significantly between the two groups. The authors suggested that higher doses might be needed to lower fasting blood sugar and HbA1c.
Carnosic Acid AMP-Activated Protein Kinase Activation — The Metformin Pathway
The mechanism behind sage's antidiabetic effect is largely attributable to carnosic acid, a phenolic diterpene concentrated in the leaves of Salvia officinalis and its close relative Rosmarinus officinalis (rosemary). In cell-culture studies carnosic acid activates AMP-activated protein kinase (AMPK): in a 2017 study in rat L6 muscle cells, 2.0 µmol/L carnosic acid raised glucose uptake to 226% of control, similar to maximum insulin (201%) and metformin (213%), and an AMPK blocker reduced the effect.
AMP-activated protein kinase is the central cellular energy sensor. When adenosine triphosphate (ATP) levels drop and adenosine monophosphate (AMP) levels rise (the cell is energy-stressed), AMP-activated protein kinase is activated and triggers a coordinated cellular response:
- Catabolic pathways are switched on — fatty acid oxidation, glucose uptake by skeletal muscle (insulin-independent movement of the glucose transporter type 4 (GLUT4) to the cell surface), mitochondrial biogenesis
- Anabolic pathways are switched off — fatty acid synthesis, cholesterol synthesis, protein synthesis, hepatic gluconeogenesis
- Whole-body energy substrate flows shift toward oxidation and away from storage
This is exactly the metabolic shift that produces the antidiabetic effect of metformin, the first-line oral type 2 diabetes drug. Metformin activates AMP-activated protein kinase indirectly (by partial complex-I inhibition that drops ATP/AMP ratio). Berberine, the alkaloid in goldenseal and barberry that has its own evidence base in type 2 diabetes, also activates AMP-activated protein kinase. Carnosic acid does so as well in a 2017 cell-culture study in rat muscle cells, and rosemary extract, which contains carnosic acid, activated AMP-activated protein kinase in HepG2 liver cells in a 2013 study. These are laboratory results, not measurements of blood levels or effects in people taking sage.
The implication drawn from this laboratory work is that sage may share its primary mechanism with metformin and berberine. The effect sizes are not equal — metformin's AMP-activated protein kinase activation is more potent than carnosic acid's on a milligram-per-milligram basis — but the proposed metabolic profile is similar: improved insulin sensitivity, reduced fasting glucose and an improved lipid profile.
The “metformin-like” label for sage comes from a 2006 animal study by Lima and colleagues. In normal mice, drinking sage tea instead of water for 14 days lowered fasting blood sugar, and liver cells (hepatocytes) from healthy rats that drank sage tea made less new glucose (gluconeogenesis) in response to the hormone glucagon — effects the authors compared with metformin. In liver cells from diabetic rats, however, none of these effects appeared, and the authors wrote that sage tea “does not possess antidiabetic effects at this level”. They suggested that sage might be useful as a food supplement for preventing type 2 diabetes in people at risk.
Insulin Sensitization in Liver & Muscle
AMP-activated protein kinase activation in the liver suppresses hepatic gluconeogenesis — the principal driver of fasting hyperglycemia in type 2 diabetes. The liver of an untreated type 2 diabetic produces inappropriately large amounts of glucose overnight (the dawn phenomenon and the smoldering basal gluconeogenesis), even with normal-to-elevated insulin levels, because the liver becomes insulin-resistant. Metformin's primary therapeutic effect is suppression of hepatic gluconeogenesis. For sage, the evidence on this point is from animals: in the 2006 Lima study, liver cells from healthy sage-tea-drinking rats made less glucose in response to glucagon, but liver cells from diabetic rats did not.
AMP-activated protein kinase activation in skeletal muscle increases GLUT4 glucose-transporter translocation to the muscle cell membrane, which improves insulin-independent glucose uptake. This is also the mechanism by which exercise produces its acute glucose-lowering effect — exercise activates AMP-activated protein kinase in working muscle. Carnosic acid raised glucose uptake through AMP-activated protein kinase in a 2017 cell-culture study in rat L6 muscle cells, but it did not increase the amount of GLUT4 (or GLUT1) transporter at the cell surface — so in that study carnosic acid did not work through the GLUT4 movement seen with exercise.
The proposed net effect at the whole-body level is improved insulin sensitivity. Insulin levels needed for any given glucose disposal go down, the demand on the pancreatic beta cells goes down, and (in the early years of type 2 diabetes when beta cells are still functional) the natural progression from insulin resistance with hyperinsulinemia to outright insulin insufficiency is delayed. This is the same broad clinical benefit that lifestyle intervention, metformin, and the sodium-glucose cotransporter-2 (SGLT2) inhibitors all share, and it is the benefit profile proposed for sage as an add-on.
Why Sage Also Improves Cholesterol & Triglycerides
The lipid-improving effects observed in the Kianbakht trials are also explainable by the AMP-activated protein kinase mechanism. AMP-activated protein kinase suppresses two anabolic enzymes critical to lipid synthesis:
- 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase — the rate-limiting enzyme of cholesterol synthesis in the liver, and the target of the statin drug class. AMP-activated protein kinase phosphorylates and inactivates HMG-CoA reductase, reducing endogenous cholesterol synthesis. This is the molecular reason that AMP-activated protein kinase-activating interventions (metformin, exercise, sage extract) tend to lower low-density lipoprotein cholesterol.
- Acetyl-CoA carboxylase — the rate-limiting enzyme of fatty acid synthesis in the liver. AMP-activated protein kinase phosphorylates and inactivates acetyl-CoA carboxylase, suppressing hepatic lipogenesis and consequently triglyceride synthesis. This is why AMP-activated protein kinase-activating interventions tend to lower fasting triglycerides.
The high-density lipoprotein-increasing effect observed in the Kianbakht trials is more unusual and not fully mechanistically characterized. Some of it may reflect improved insulin sensitivity (which usually moves high-density lipoprotein upward), and some may reflect direct effects on apolipoprotein A-I (ApoA-I) production or reverse-cholesterol-transport pathways. The lipid sub-profile of sage adjunct therapy — low-density lipoprotein down, triglycerides down, high-density lipoprotein up — is essentially what an ideal lipid intervention would produce, and parallels the lipid effect of regular moderate-intensity exercise. In the 2023 meta-analysis that pooled three trials in people with diabetes, however, only total cholesterol and LDL fell significantly; triglycerides (p=0.09) and high-density lipoprotein (p=0.18) did not change significantly.
For people with metabolic syndrome (high triglycerides, low high-density lipoprotein, insulin resistance), this lipid pattern is the standard target. The individual Kianbakht trials reported changes in the favourable direction for each of these blood fats, while the pooled 2023 analysis found the triglyceride and high-density lipoprotein changes not statistically significant.
Alpha-Glucosidase Inhibition & Postprandial Spikes
A secondary mechanism contributing to sage's antidiabetic effect is inhibition of alpha-glucosidase, the brush-border enzyme that hydrolyzes complex carbohydrates to absorbable monosaccharides in the small intestine. Inhibiting this enzyme slows the postprandial glucose absorption and flattens the postprandial glucose spike. Acarbose, the prescription drug used primarily in East Asia for postprandial-dominant type 2 diabetes, works by this mechanism.
Several in-vitro studies have shown that sage leaf extract and individual sage constituents (rosmarinic acid, the essential-oil monoterpenes) inhibit alpha-glucosidase at clinically relevant concentrations. This effect is not unique to sage — many polyphenol-rich plant extracts share it — but it adds to sage's overall antidiabetic profile and may explain the postprandial glucose improvement observed in the Kianbakht trials in addition to the fasting glucose improvement.
In this reasoning, an alpha-glucosidase effect would act on carbohydrate eaten at the same time, so it would be larger when sage is taken with a carbohydrate-containing meal than between meals. The trial abstracts do not say whether the doses were timed to meals.
Carnosic Acid, Adipocytes, & Weight Metabolism
Beyond glucose and lipid effects, carnosic acid has been shown in cell-culture studies to inhibit adipocyte differentiation, suppress lipid accumulation in maturing adipocytes, and promote browning of white adipose tissue (induction of uncoupling protein 1 (UCP1) expression). In animal models of diet-induced obesity, carnosic acid and carnosic-acid-enriched plant extracts (rosemary or sage extracts standardized to carnosic-acid content) modestly reduce body weight gain, reduce hepatic steatosis, and improve insulin sensitivity.
The human trial evidence for sage specifically as a weight-loss intervention is limited. In the 2016 Kianbakht trial, which measured body mass index, sage extract did not change it significantly over 2 months.
Larger weight effects belong to medications specifically indicated for weight loss (glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 inhibitors with weight benefit) and to lifestyle intervention.
Culinary Sage vs Therapeutic Extract Dosing
A culinary use of sage (a teaspoon of dried leaf in a recipe serving four people) delivers approximately 250 to 500 mg of dried sage leaf per serving, scattered over a single meal once or twice a week. The therapeutic dose used in the Kianbakht trials was approximately 500 mg of hydroalcoholic extract three times daily — corresponding to approximately 2 to 3 grams of dried-leaf-equivalent per day, every day, for 3 months. The therapeutic dose is roughly an order of magnitude higher than typical kitchen exposure, and is concentrated and consistent in a way that culinary use is not.
Using sage in most savory dishes (sage-rubbed pork loin, sage-roasted vegetables, brown-butter-and-sage pasta, sage-and-onion stuffing) adds a small amount but does not reach the amount used in the Kianbakht trials, which gave a standardized extract in capsules.
A strong sage tea — 1 tablespoon of dried leaf in 250 mL of just-off-boil water, steeped 10 minutes covered — is the main non-capsule form. The sage trials do not report how such a tea compares with the 500 mg three-times-daily extract dose. Tea strength varies from cup to cup, and tea carries somewhat more thujone than a thujone-controlled extract.
The only human sage-tea study is a small 2009 pilot from Portugal (Sá and colleagues): six healthy women aged 40 to 50 drank sage tea for four weeks in a non-randomized crossover design. The tea had no effect on blood sugar, but LDL and total cholesterol fell and HDL cholesterol rose during treatment and two weeks after it. No liver damage (hepatotoxic effects) or other adverse effects were seen.
Sage vs Metformin — Adjunct, Not Replacement
In the trials, sage was tested in type 2 diabetes as an adjunct against placebo, not as a metformin replacement. Metformin has 60+ years of clinical experience, decades of large-scale outcome data including the United Kingdom Prospective Diabetes Study (UKPDS) demonstrating reduction in diabetes-related complications, and a dose-response profile that allows clinicians to titrate up to substantial hemoglobin A1c reductions (1.0 to 1.5 percentage points at maximum tolerated dose). The 2023 meta-analysis of three sage trials pooled a hemoglobin A1c reduction of 0.94 percentage points over 2 to 3 months, with no comparable long-term outcome data.
The 2016 Kianbakht trial tested sage as an add-on to existing drugs. 100 people with type 2 diabetes and high cholesterol were already taking 15 mg glyburide, 2000 mg metformin and 10 mg atorvastatin daily; 50 added sage leaf extract (one 500 mg capsule three times a day) and 50 added placebo, for 2 months. Compared with placebo, the sage group had lower fasting glucose, 2-hour after-meal glucose, HbA1c, total and LDL cholesterol and triglycerides, and higher HDL cholesterol. Body mass index, liver enzymes and creatinine did not change significantly, and no adverse effect was reported.
What the research reports for the situations people most often ask about:
- People on metformin whose hemoglobin A1c is still above goal — in the 2016 trial, sage added to glyburide, metformin and atorvastatin lowered HbA1c further than placebo, and the 2023 meta-analysis pooled a 0.94-point reduction. In the 2013 Behradmanesh trial of 80 people with poorly controlled type 2 diabetes, however, fasting sugar and HbA1c did not change significantly compared with placebo.
- People with prediabetes or early type 2 diabetes (hemoglobin A1c 5.7 to 7.0%) who are reluctant to start metformin — none of the sage trials described on this page enrolled people with prediabetes, and the trials lasted 2 to 3 months.
- People on metformin who also have mild-to-moderate high cholesterol (dyslipidemia) — in the 2016 trial, sage added to atorvastatin (a statin) lowered total and LDL cholesterol and triglycerides further and raised HDL. The trials did not test sage as a way to avoid or delay a statin.
- People who cannot tolerate metformin's gastrointestinal side effects — sage at the Kianbakht dose has not been compared with metformin head-to-head; no adverse effects were reported in the Kianbakht trials.
The sage trials were placebo-controlled studies in type 2 diabetes or high blood fats lasting 2 to 3 months. None enrolled people with type 1 diabetes (where the deficit is insulin production, not insulin sensitivity) or with an acute diabetic emergency (decompensation), and none compared sage with prescription treatment for severe uncontrolled type 2 diabetes (hemoglobin A1c above 9%).
Cautions — Hypoglycemia, Drug Interactions, Thujone
- Additive hypoglycemia risk with insulin or sulfonylureas — sage extract lowered blood sugar in trials, which raises a concern for additive low blood sugar (hypoglycemia) in people on insulin or on sulfonylureas (glipizide, glyburide, glimepiride). A home fingerstick glucose check is how such a drop shows up. The 2013 Kianbakht abstract does not state the patients' background diabetes drugs; the 2016 Kianbakht trial added sage to 15 mg glyburide (a sulfonylurea), 2000 mg metformin and 10 mg atorvastatin daily, and no adverse effect was reported. Combination with insulin or a sulfonylurea can call for a lower dose of the antidiabetic drug.
- Modest additive effect with metformin — in the 2016 trial sage was taken with 2000 mg metformin daily and no adverse effect was reported. A combined effect matters when later medication doses are adjusted.
- Liver function — standardized leaf-extract doses at 500 mg three times daily for 2 to 3 months did not produce abnormal liver enzymes in the Kianbakht trials. High-dose sage essential oil internally is a different matter and has rare case reports of hepatotoxicity; the trial liver results cover the leaf-extract form, not essential-oil capsules.
- Pregnancy — sage extract or tea at therapeutic doses in pregnancy raises uterotonic (womb-contracting) concerns. Standard care for gestational diabetes is lifestyle change first, then insulin if needed. Culinary amounts are a much smaller exposure.
- Epilepsy — standardized leaf extract from low-thujone chemotypes or Spanish sage carries far less thujone than common-sage essential-oil capsules at high dose, which are the form of concern for people with epilepsy.
- Pre-surgical bleeding risk — sage has modest anticoagulant activity in some in-vitro studies. A common conservative practice is a pause of 7 to 14 days before elective surgery, and surgical teams ask about herbal extracts for this reason. At typical therapeutic doses the concern is probably small.
- Iron absorption — polyphenol-rich tea taken with iron-containing meals can reduce nonheme-iron absorption. For people with iron deficiency or taking iron supplements, a gap of 1 to 2 hours between sage tea and iron-rich meals is the spacing usually described to limit this effect.
Key Research Papers
- Kianbakht S, Dabaghian FH (2013). Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial. Complementary Therapies in Medicine 21(5):441-6. — PubMed PMID: 24050577
- Kianbakht S, Abasi B, Perham M, Hashem Dabaghian F (2011). Antihyperlipidemic effects of Salvia officinalis L. leaf extract in patients with hyperlipidemia: a randomized double-blind placebo-controlled clinical trial. Phytotherapy Research 25(12):1849-53. — PubMed PMID: 21506190
- Kianbakht S, Nabati F, Abasi B (2016). Salvia officinalis (Sage) Leaf Extract as Add-on to Statin Therapy in Hypercholesterolemic Type 2 Diabetic Patients: a Randomized Clinical Trial. International Journal of Molecular and Cellular Medicine 5(3):141-148. — PubMed PMID: 27942500
- Behradmanesh S, Derees F, Rafieian-Kopaei M (2013). Effect of Salvia officinalis on diabetic patients. Journal of Renal Injury Prevention 2(2):51-4. — PubMed PMID: 25340127
- Abdollahi A, Adelibahram F, Ghassab-Abdollahi N, Araj-Khodaei M, Parsian Z, Mirghafourvand M (2023). The effect of Salvia officinalis on blood glycemic indexes and blood lipid profile in diabetic patients: a systematic review and meta-analysis. Journal of Complementary and Integrative Medicine 20(3):521-529. — PubMed PMID: 35106985
- Sá CM, Ramos AA, Azevedo MF, Lima CF, Fernandes-Ferreira M, Pereira-Wilson C (2009). Sage tea drinking improves lipid profile and antioxidant defences in humans. International Journal of Molecular Sciences 10(9):3937-3950. — PubMed PMID: 19865527
- Lima CF, Azevedo MF, Araujo R, Fernandes-Ferreira M, Pereira-Wilson C (2006). Metformin-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention? British Journal of Nutrition 96(2):326-33. — PubMed PMID: 16923227
- Naimi M, Vlavcheski F, Murphy B, Hudlicky T, Tsiani E (2017). Carnosic acid as a component of rosemary extract stimulates skeletal muscle cell glucose uptake via AMPK activation. Clinical and Experimental Pharmacology and Physiology 44(1):94-102. — PubMed PMID: 27716981
- Tu Z, Moss-Pierce T, Ford P, Jiang TA (2013). Rosemary (Rosmarinus officinalis L.) extract regulates glucose and lipid metabolism by activating AMPK and PPAR pathways in HepG2 cells. Journal of Agricultural and Food Chemistry 61(11):2803-10. (Carnosic acid AMPK mechanism, parallel evidence from rosemary.) — PubMed PMID: 23432097
- Christensen KB, Jørgensen M, Kotowska D, Petersen RK, Kristiansen K, Christensen LP (2010). Activation of the nuclear receptor PPARγ by metabolites isolated from sage (Salvia officinalis L.). Journal of Ethnopharmacology 132(1):127-33. — PubMed PMID: 20696231
- Hardie DG, Ross FA, Hawley SA (2012). AMP-activated protein kinase: a target for drugs both ancient and modern. Chemistry & Biology 19(10):1222-36. — PubMed PMID: 23102217
- Madiraju AK et al. (2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510(7506):542-6. (Mechanistic context for AMPK-activating antidiabetic intervention.) — PubMed PMID: 24847880
PubMed Topic Searches
Connections
- All Herbs
- Sage Overview
- Sage Benefits Hub
- Sage for Cognitive Function
- Sage for Menopause
- Sage for Antimicrobial & Throat
- Rosemary (Carnosic Acid Sister)
- Berberine (AMP-Activated Protein Kinase Sister)
- Cinnamon (Insulin Sensitivity)
- Fenugreek
- Type 2 Diabetes
- Insulin Resistance
- Metabolic Syndrome
- High Cholesterol / Dyslipidemia
- Hemoglobin A1c
- Continuous Glucose Monitor
- Metformin — the AMP-activated protein kinase-activating first-line drug sage is benchmarked against throughout this page; sage is dosed as an adjunct alongside it, never as a replacement.
- Covered in depth on its own page: Type 2 Diabetes
- History